Back to Search Start Over

SIRPγ-expressing cancer stem-like cells promote immune escape of lung cancer via Hippo signaling

Authors :
Chuan Xu
Guoxiang Jin
Hong Wu
Wei Cui
Yu-Hui Wang
Rajesh Kumar Manne
Guihua Wang
Weina Zhang
Xian Zhang
Fei Han
Zhen Cai
Bo-Syong Pan
Che-Chia Hsu
Yiqiang Liu
Anmei Zhang
Jie Long
Hongbo Zou
Shuang Wang
Xiaodan Ma
Jinling Duan
Bin Wang
Weihui Liu
Haitao Lan
Qing Xiong
Gang Xue
Zhongzhu Chen
Zhigang Xu
Mark E. Furth
Sarah Haigh Molina
Yong Lu
Dan Xie
Xiu-Wu Bian
Hui-Kuan Lin
Source :
The Journal of Clinical Investigation, Vol 132, Iss 5 (2022)
Publication Year :
2022
Publisher :
American Society for Clinical Investigation, 2022.

Abstract

Cancer stem-like cells (CSLCs) acquire enhanced immune checkpoint responses to evade immune cell killing and promote tumor progression. Here we showed that signal regulatory protein γ (SIRPγ) determined CSLC properties and immune evasiveness in a small population of lung adenocarcinoma (LUAD) cancer cells. A SIRPγhi population displayed CSLC properties and transmitted the immune escape signal through sustaining CD47 expression in both SIRPγhi and SIRPγlo/– tumor cells. SIRPγ bridged MST1 and PP2A to facilitate MST1 dephosphorylation, resulting in Hippo/YAP activation and leading to cytokine release by CSLCs, which stimulated CD47 expression in LUAD cells and consequently inhibited tumor cell phagocytosis. SIRPγ promoted tumor growth and metastasis in vivo through YAP signaling. Notably, SIRPγ targeting with genetic SIRPγ knockdown or a SIRPγ-neutralizing antibody inhibited CSLC phenotypes and elicited phagocytosis that suppressed tumor growth in vivo. SIRPG was upregulated in human LUAD and its overexpression predicted poor survival outcome. Thus, SIRPγhi cells serve as CSLCs and tumor immune checkpoint–initiating cells, propagating the immune escape signal to the entire cancer cell population. Our study identifies Hippo/YAP signaling as the first mechanism by which SIRPγ is engaged and reveals that targeting SIRPγ represents an immune- and CSLC-targeting strategy for lung cancer therapy.

Subjects

Subjects :
Immunology
Medicine

Details

Language :
English
ISSN :
15588238
Volume :
132
Issue :
5
Database :
Directory of Open Access Journals
Journal :
The Journal of Clinical Investigation
Publication Type :
Academic Journal
Accession number :
edsdoj.9d232ee19b4520b69e25795aaa76fb
Document Type :
article
Full Text :
https://doi.org/10.1172/JCI141797